Corbus Pharmaceuticals
CRBP
72 hedge funds and large institutions have $19.7M invested in Corbus Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 24 reducing their positions, and 18 closing their positions.
59% more call options, than puts
Call options by funds: $240K | Put options by funds: $151K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.19% less ownership
Funds ownership: 1.19% → 1% (-0.19%)
12% less funds holding
Funds holding: 82 → 72 (-10)
28% less capital invested
Capital invested by funds: $27.3M → $19.7M (-$7.56M)
38% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 24
56% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$403K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$229K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$170K |
| 4 |
D.E. Shaw & Co
New York
|
+$72.2K |
| 5 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
+$51.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$1.24M |
| 2 |
Morgan Stanley
New York
|
-$866K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$491K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$431K |
| 5 |
PCM
Penserra Capital Management
Orinda,
California
|
-$330K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EGM
76
Engineers Gate Manager
New York
| – | -$12K | -670 | Closed |
|
|
AWM
77
Aries Wealth Management
Portland,
Maine
| – | -$9K | -513 | Closed |
|
|
PPA
78
Parametric Portfolio Associates
Seattle,
Washington
| – | -$7K | -353 | Closed |
|
|
CT
79
Cambridge Trust
Cambridge,
Massachusetts
| – | -$2K | -133 | Closed |
|
|
CA
80
CoreCap Advisors
Southfield,
Michigan
| – | -$1K | -25 | Closed |
|
81
Bank of America
Charlotte,
North Carolina
| – | -$292 | -22 | -92% |
|
CRBP Hedge Fund Activity: Q1 2022 in Review
72 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q1 2022, worth a combined $19.7M — down 28% from $27.3M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CRBP and 8 opened new positions — a net loss of 10 holders — while 24 trimmed existing stakes and 15 added.
The largest buyer was Renaissance Technologies, adding an estimated $403K. The largest seller was ETF Managers Group, cutting an estimated $1.24M.
- 72 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q1 2022, down from 82 in Q4 2021.
- Funds reported $19.7M of Corbus Pharmaceuticals stock for Q1 2022, down 28% quarter-over-quarter.
- 8 funds opened new Corbus Pharmaceuticals positions in Q1 2022 and 18 closed out, a net change of -10 holders.
- The largest Corbus Pharmaceuticals buyer in Q1 2022 was Renaissance Technologies, an estimated $403K added.
- The largest Corbus Pharmaceuticals seller in Q1 2022 was ETF Managers Group, an estimated $1.24M sold.
Based on aggregated 13F filings for Q1 2022.